Abeona Therapeutics is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Type
Public
HQ
Dallas, US
Founded
2013
Size (employees)
19 (est)+217%
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US
Report incorrect company information

Key People/Management at Abeona Therapeutics

Carsten Thiel

Carsten Thiel

CEO
Timothy Miller

Timothy Miller

President & Chief Scientific Officer
Jeffrey B. Davis

Jeffrey B. Davis

COO
Juan Ruiz MD, PhD

Juan Ruiz MD, PhD

Chief Medical Officer
Stephen B. Thompson

Stephen B. Thompson

Chief Accounting Officer
Kaye Spratt PhD

Kaye Spratt PhD

Senior Vice President, Regulatory Affairs
Show more

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy
Show all (1)
Report incorrect company information

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Financials

Abeona Therapeutics's revenue was reported to be $837 k in FY, 2017
USD

Revenue (Q1, 2018)

2.6 m

Net income (Q1, 2018)

(8.5 m)

EBIT (Q1, 2018)

(8.6 m)

Market capitalization (22-Jun-2018)

775.8 m

Closing share price (22-Jun-2018)

16.4

Cash (31-Mar-2018)

132 m
Abeona Therapeutics's current market capitalization is $775.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2 m925 k1 m889 k837 k

Revenue growth, %

(55%)12%(15%)

General and administrative expense

13.3 m10.9 m

R&D expense

10.7 m17 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

189 k208 k247 k236 k258 k285 k235 k214 k184 k186 k217 k219 k2.6 m

General and administrative expense

642 k733 k868 k795 k1.7 m4.7 m4.4 m3.7 m2.4 m3 m2.6 m2.2 m2.9 m

R&D expense

236 k72 k81 k73 k453 k1.6 m1.9 m3 m2.7 m2.2 m5.8 m3.3 m8.2 m

Operating expense total

885 k805 k950 k869 k2.3 m6.4 m6.4 m6.9 m5.4 m5.5 m8.7 m5.6 m11.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

424 k11.5 m40.1 m69.1 m137.8 m

Accounts Receivable

107 k

Inventories

77 k315 k155 k

Current Assets

575 k11.6 m40.6 m69.4 m140.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

899 k299 k55 k165 k7.9 m43.3 m37.4 m34.3 m31.2 m63.2 m58.3 m56.5 m132 m

Accounts Receivable

64 k

Inventories

1.8 m

Current Assets

1 m440 k203 k244 k8.2 m43.7 m37.8 m34.6 m31.9 m63.8 m59.3 m58.4 m134.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)(27.3 m)

Depreciation and Amortization

3 k11 k551 k825 k741 k

Inventories

174 k77 k(287 k)160 k

Accounts Payable

(1.2 m)33 k(1.2 m)2.8 m(1.3 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(157 k)(128 k)(12.5 m)(1.5 m)(2 m)(12.2 m)(5.5 m)(12.2 m)(14.9 m)(5.2 m)(8.5 m)

Depreciation and Amortization

1 k1 k118 k401 k174 k355 k577 k250 k174 k

Accounts Payable

1.1 m1.3 m1.6 m638 k(1.1 m)1 m1.2 m1 m1.5 m3.5 m

Cash From Operating Activities

(7.5 m)(5.6 m)(9.6 m)(4.1 m)
USDY, 2018

Revenue/Employee

136.7 k

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Abeona Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Abeona Therapeutics News and Updates

Alpha N-Acetylglucosaminidase Market Comprehensive Analysis on Leading Key Players: Abeona Therapeutics, UniQure, Lesinidase Alfa

Alpha N-Acetylglucosaminidase Market Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information